Articles related to Infectious Diseases

How does the diagnostic performance of home antigen tests change during the course of SARS-CoV-2 infection? Symptomatic individuals with an initial negative home antigen test result for SARS-CoV-2 infection should test again one to two days later because test sensitivity seems to peak several days after illness onset.

The Centers for Disease Control and Prevention (CDC) warns that the incidence of sexually transmitted diseases (STDs) in the US continued to rise during the first year of the pandemic. For the first time in seven years, the overall number of reported STD cases was lower than the previous year, but the CDC attributed the drop-off to a decline in reported cases of chlamydia — the nation’s most common STD — that was likely a result of pandemic-related interruptions to screening.

This quiz tests your knowledge on the appropriate screening follow-up from a 23-year-old woman who was treated for gonococcal arthritis. After a physical exam that showed a complete resolution of symptoms, which screening test is the next course of action? A CD4 lymphocyte subset? Serum IgA level? Total hemolytic complement (CH50) level? Is any additional testing even needed?

Although there now exist many safe and approved therapeutics for non-hospitalized patients who have COVID-19 or one of its variants, these therapies are often distributed in an ineffective and unequitable manner, according to an article published by JAMA Network. The article highlights many of the available therapies and how to distribute them fairly to patients when demand exceeds available supply.

Amy Watson became famous for coining the term “COVID long hauler” to describe people, such as herself, who suffer from the effects of the respiratory disease over an extended period. These long-haul symptoms can include fever, body aches, and fatigue. Watson herself says she rarely goes more than a few hours without suffering a fever, nearly two years after first contracting COVID-19. GoodRx Health chronicles Amy Watson’s story and what it’s like for people suffering from long COVID.

At the outset of the pandemic, biotechnology company Novavax was one of the frontrunners to bring a vaccine against COVID-19 to market. But nearly two years later, Novavax’s vaccine has yet to appear. In a compelling article, the BMJ details the repeated delays and setbacks that have torpedoed Novavax’s once-promising vaccine candidate and rendered it unnecessary now that other vaccines from Pfizer, Moderna, and AstraZeneca flood the global marketplace.